Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason M Pogue

Showing results (1-10 of 167) with videos related to

Pageof 17
Sort By:
Antimicrobial Agents and Chemotherapy|June 13, 2023
Case Commentary: When Voldemort Meets Sauron: Treatment Considerations for Emerging Dual-Carbapenemase-Producing Extensively Drug-Resistant Pseudomonas aeruginosaWalaiporn Wangchinda, Jason M Pogue
The Annals of Pharmacotherapy|September 6, 2012
Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trialCesar Alaniz, Jason M Pogue
Expert Opinion on Pharmacotherapy|September 10, 2019
Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO worldJason M Pogue, Emily L Heil
Pharmacotherapy|October 27, 2015
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and ManagementKeith S Kaye, Jason M Pogue
Journal of Clinical Microbiology|March 28, 2020
The Clinical Impact of a Negative Molecular β-Lactamase Gene Test for <i>Enterobacteriaceae</i>: Let's Not Let Perfect Be the Enemy of Really GoodJason M Pogue, Emily L Heil
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 29, 2025
The Antibiotic Pipeline Has Delivered for Drug-Resistant Gram-Negative Pathogens, Now Global Access Must FollowJason M Pogue, David van Duin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Actually, it may be time to return to colistin and meropenem in some patients infected with Carbapenem-resistant A. baumannii (CRAB)Jason M Pogue, Keith S Kaye
Advances in Experimental Medicine and Biology|August 1, 2019
Toxicity in PatientsJason M Pogue, Vincent H Tam
Expert Review of Anti-Infective Therapy|September 24, 2013
Is there really no benefit to combination therapy with colistin?Jason M Pogue, Keith S Kaye
Open Forum Infectious Diseases|April 15, 2020
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging OptionsErin K McCreary, Jason M Pogue
Pageof 17

Showing results (1-10 of 167) with videos related to

Sort By:
Pageof 17
Antimicrobial Agents and Chemotherapy|June 13, 2023
Case Commentary: When Voldemort Meets Sauron: Treatment Considerations for Emerging Dual-Carbapenemase-Producing Extensively Drug-Resistant Pseudomonas aeruginosaWalaiporn Wangchinda, Jason M Pogue
The Annals of Pharmacotherapy|September 6, 2012
Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trialCesar Alaniz, Jason M Pogue
Expert Opinion on Pharmacotherapy|September 10, 2019
Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO worldJason M Pogue, Emily L Heil
Pharmacotherapy|October 27, 2015
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and ManagementKeith S Kaye, Jason M Pogue
Journal of Clinical Microbiology|March 28, 2020
The Clinical Impact of a Negative Molecular β-Lactamase Gene Test for <i>Enterobacteriaceae</i>: Let's Not Let Perfect Be the Enemy of Really GoodJason M Pogue, Emily L Heil
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 29, 2025
The Antibiotic Pipeline Has Delivered for Drug-Resistant Gram-Negative Pathogens, Now Global Access Must FollowJason M Pogue, David van Duin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Actually, it may be time to return to colistin and meropenem in some patients infected with Carbapenem-resistant A. baumannii (CRAB)Jason M Pogue, Keith S Kaye
Advances in Experimental Medicine and Biology|August 1, 2019
Toxicity in PatientsJason M Pogue, Vincent H Tam
Expert Review of Anti-Infective Therapy|September 24, 2013
Is there really no benefit to combination therapy with colistin?Jason M Pogue, Keith S Kaye
Open Forum Infectious Diseases|April 15, 2020
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging OptionsErin K McCreary, Jason M Pogue
Pageof 17